@caminalm

Internal Medicine. Bedside-medicine. Systemic Autoimmune Diseases. Can't walk away from life's work and passion.

 Asturias, Spain.
researchgate.net/profile/Luis-Caminal-Montero/research
Joined December 2013
  • Tweets10.7K
  • Following457
  • Followers1K
83Media
Luis Caminal retweeted
JAMA
@JAMA_currentOct 24
🧵 Presented at #KidneyWk: Meta-analysis: Across randomized clinical trials involving patients with cardiovascular disease, #HeartFailure, #ChronicKidneyDisease, or #diabetes, sodium-glucose cotransporter 2 (#SGLT2) inhibitor use was associated with small increases in hemoglobin and hematocrit vs control. These findings support a consistent hematologic effect across disease settings, although the clinical significance remains uncertain. ja.ma/4sllrNF @ASNKidney
4
37
3
158
17,349
Luis Caminal retweeted
Dr. John Cush
@RheumNowOct 24
FDA has granted Fast Track designation to EG-501 (Evergreen), investigational Rx for cognitive impairment with neuropsychiatric systemic lupus erythematosus (NPSLE), following positive results from the phase 2 ClearMEMory study buff.ly/hFqbzRF
1
7
16
1,104
Luis Caminal retweeted
NEJM
@NEJMOct 23
There are currently no approved therapies available for Sjögren’s disease, and trials of multiple biologic and targeted approaches have been negative or inconclusive. Research findings are summarized in a new Quick Take video. nej.md/4BcjQxL
Illustration showing a patient with Sjögren’s disease and ianalumab, an IgG1 monoclonal antibody that depletes B cells and blocks B-cell activation and survival through the BAFF receptor.

ALT Illustration showing a patient with Sjögren’s disease and ianalumab, an IgG1 monoclonal antibody that depletes B cells and blocks B-cell activation and survival through the BAFF receptor.

4
24
2
111
17,764
Luis Caminal retweeted
Paul Breillat@PBreillatOct 23
jamanetwork.com/journals/jam…

Rituximab vs Azathioprine for Eosinophilic Granulomatosis With Polyangiitis Maintenance

This Preliminary Communication investigates whether rituximab is more effective than azathioprine at maintaining remission in patients with eosinophilic granulomatosis with polyangiitis.

jamanetwork.com
2
2
93
Ianalumab in #Sjögren’s Disease — A First Step | New England Journal of Medicine nejm.org/doi/full/10.1056/NE…

Ianalumab in Sjögren’s Disease — A First Step | NEJM

Sjögren’s disease has long frustrated clinicians, trialists, and — most important — patients for whom effective treatments remain elusive. Glandular dysfunction causes dryness; fatigue and pain add...

nejm.org
5
6
393
Ianalumab for the Treatment of Patients with # Sjögren’s Disease | New England Journal of Medicine nejm.org/doi/full/10.1056/NE…

Ianalumab for the Treatment of Patients with Sjögren’s Disease | NEJM

Sjögren’s disease is a complex, systemic autoimmune disease with no approved targeted therapies. Ianalumab is an IgG1 monoclonal antibody with a dual mechanism of action, depleting B cells through ...

nejm.org
3
10
566
Please read this beautiful tribute in honor of Dr Daniel Kastner MD, PhD. It tells how he started, at 12 yrs old w/ a science fair, and onwards to understand and advance science, while caring deeply for his patients. His impact is beyond words. Thanks.🧡 sciencedirect.com/science/ar…
7
14
491
Long-term comparative outcomes of rituximab and belimumab in lupus patients academic.oup.com/rheumatolog…

Long-term comparative outcomes of rituximab and belimumab in lupus patients

AbstractObjectives. Although rituximab and belimumab are recommended for SLE and LN, direct long-term comparative evidence is limited. We aimed to compare

academic.oup.com
1
14
31
1,816
Luis Caminal retweeted
Chris Wincup@chriswincupOct 17
🦴 Lupus arthritis isn’t simply RA in #SLE Our new review synthesises evidence for distinct synovial immunology, highlights major gaps in tissue research, and calls for single-cell studies and better imaging-based outcomes to advance precision treatment doi.org/10.3389/fimmu.2026.1…
1
50
139
4,973
Luis Caminal retweeted
Eric Topol
@EricTopolOct 14
The immune system as the explanation for why the Shingles vaccine has shown protection vs dementia in 4 natural experiments pnas.org/doi/10.1073/pnas.26…
25
281
20
1,093
58,518
Not Available in Your Country | New England Journal of Medicine nejm.org/doi/full/10.1056/NE…

Not Available in Your Country | NEJM

Reflexively reaching for his phone to seek the answer to a medical student’s question, a physician educator finds that a widely used medical AI agent has been banned in his country.

nejm.org
1
194
Luis Caminal retweeted
Eric Topol
@EricTopolOct 6
Do statins help prevent glaucoma? bjo.bmj.com/content/early/20…
11
49
4
214
30,297
Luis Caminal retweeted
Dr. John Cush
@RheumNowOct 4
Amgen announced topline results from the Phase 3 OASIZ 301 study showing the efficacy of dazodalibep in Sjögren's dz, w/ signif ESSDAI improvements at wek 48. DAZO is a CD40L antagonist fusion protein buff.ly/y9rQaOA
1
8
1
16
1,636
The Avacopan Fraud Story from my Update in Nephrology 2026: What's New in NephronTown youtu.be/cf1uenkWpYU?si=65Bp…

Nephrology Update 2026: The Avacopan Story

This is one beat of my Nephrology Update for 2026: What's New in Ne...

youtube.com
1
25
1
86
15,433
Rituximab without the infusion? A 2026 Rheumatology study tested ultra-low-dose subcutaneous rituximab in selected RA patients with stable low disease activity. Model-based PK met the prespecified noninferiority criterion, with similar B-cell counts and disease control signals. But this was a small, open-label study — not proof that SC rituximab is equivalent to standard IV therapy. Promising convenience signal. Needs confirmation. #RheumatoidArthritis #Rituximab #Rheumatology #Biologics #MedicalEducation
🤖 Made with AI
2
29
1
84
3,248
Luis Caminal retweeted
The BMJ
@bmj_latestOct 2
GLP-1 drugs have changed the face of weight loss. But amid high prices and obstacles to access, people are attempting experimental small doses. Are the drugs effective at these doses—and is microdosing GLP-1s safe? bmj.com/content/395/bmj-2026…

Weight loss drugs: Does microdosing GLP-1s work?

GLP-1 drugs have changed the face of weight loss. But amid high prices and obstacles to access, people are attempting experimental small doses. Are the drugs effective at these doses—and is microdo...

bmj.com
14
22
2
103
27,621
Luis Caminal retweeted
Practicon@moy_qmacSep 29
Me acabo de enterar que ya no se llamaran anti Ro 60 ni anti Ro 52 Ahora seran anti TROVE2 y anti TRIM21 Un dia triste para la reumatología sin duda.
7
80
9
552
34,334
Luis Caminal retweeted
ACR_Journals
@ACR_JournalsSep 26
Editorial in A&R: From ADVOCATE to ADVOGATE: is this the end of avacopan? doi.org/10.1002/art.70352 Figure: The history of avacopan
The history of avacopan. Initially shown to attenuate glomerulonephritis in a mouse model of ANCA-associated vasculitis in 2014, phase II and III trials quickly followed and avacopan was approved for use across the globe in late 2021 and early 2022. Following release of the Walton report in May 2025, as part of a securities fraud litigation against ChemoCentryx, investigations into the ADVOCATE trial by regulatory bodies began in early 2026

ALT The history of avacopan. Initially shown to attenuate glomerulonephritis in a mouse model of ANCA-associated vasculitis in 2014, phase II and III trials quickly followed and avacopan was approved for use across the globe in late 2021 and early 2022. Following release of the Walton report in May 2025, as part of a securities fraud litigation against ChemoCentryx, investigations into the ADVOCATE trial by regulatory bodies began in early 2026

ACR_Journals
@ACR_JournalsAug 27
New RISE registry real-world US data on avacopan: •Liver enzyme elevations were rare among 238 AAV patients, ~2-4 per 100 person-years across AST, ALT, alk phos, and bilirubin •Two confirmed cases of drug-induced liver injury occurred (0.8%), both ~9 weeks after starting. Frequent early testing is warranted A&R doi.org/10.1002/art.70304 @JYazdanyMD Figure: Time course of liver enzyme tests in two suspected cases of avacopan-induced liver injury
Time course of liver enzyme tests in two suspected cases of avacopan-induced drug-induced liver injury. Liver enzyme levels expressed as multiples of the upper limit of normal (×ULN. (a) 40s year old white woman with GPA noted to have elevated liver enzymes 62 days after initiating avacopan. Liver enzymes normalized within 6 weeks of stopping avacopan. (b). 50s year old white woman with GPA noted to have elevated liver enzymes 71 days after initiating avacopan. Liver enzymes normalized within 7 weeks of stopping avacopan

ALT Time course of liver enzyme tests in two suspected cases of avacopan-induced drug-induced liver injury. Liver enzyme levels expressed as multiples of the upper limit of normal (×ULN. (a) 40s year old white woman with GPA noted to have elevated liver enzymes 62 days after initiating avacopan. Liver enzymes normalized within 6 weeks of stopping avacopan. (b). 50s year old white woman with GPA noted to have elevated liver enzymes 71 days after initiating avacopan. Liver enzymes normalized within 7 weeks of stopping avacopan

2
9
1,708
A University of Chicago @UofC professor wrote 200 papers in a year using AI raising questions about academic publishing. Is this a good or bad idea? Is it the idea that is important, or the writing or both? Why does writing matter anymore? Tell me your thoughts !
Michael 英泉 Eisen
@mbeisenSep 23
academia 100% deserves this washingtonpost.com/education…

Using AI, a professor wrote 200 papers this year. Researchers are alarmed.

An online platform removed 257 papers written or co-written by the University of Chicago’s Nicholas Polson after other academics raised questions.

washingtonpost.com
10
5
21
14,515
Clinical Uses of Common Genetic Variants Associated with Common Diseases | New England Journal of Medicine nejm.org/doi/full/10.1056/NE…

Clinical Uses of Common Genetic Variants Associated with Common Diseases | NEJM

Twenty-five years after the draft of the human genome sequence, genomics has revolutionized many areas of biology, the diagnosis of familial and early-onset diseases, and the development of targete...

nejm.org
4
4
571
Load more